secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001104659-23-099856
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics provides pipeline update; SHINE interim shows 3-point ADAS-Cog benefit
--------------------------------------------------------------------------------

- Cash and equivalents $37.2M as of June 30, 2023; expected runway through Q3 2024.
- Total grant funding ~$171M; $81.8M remaining as of June 30, 2023.
- SHINE Phase 2 interim (n=24) showed 3-point ADAS-Cog-11 difference at Day 185 vs placebo.
- Topline data for SHINE (mild-moderate AD) and SHIMMER (DLB) expected mid-2024.
- Phase 2 START (early AD) enrolling; MAGNIFY (dry AMD) in development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923099856/0001104659-23-099856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923099856/tm2325877d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-099856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer